Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies
Takashi Kishimoto
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Anti-PEG antibodies: Current situation and countermeasures
Jiaru Fu, Ercan Wu, Guanghui Li, et al.
Nano Today (2024) Vol. 55, pp. 102163-102163
Closed Access | Times Cited: 32
Immunogenicity of biologic agents in rheumatology
Vibeke Strand, João Gonçalves, John D. Isaacs
Nature Reviews Rheumatology (2020) Vol. 17, Iss. 2, pp. 81-97
Closed Access | Times Cited: 72
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Radwa Ewaisha, Karen S. Anderson
Frontiers in Bioengineering and Biotechnology (2023) Vol. 11
Open Access | Times Cited: 42
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia
Earl Sands, Alan Kivitz, Wesley DeHaan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 40
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
Robert Terkeltaub
Drugs (2023) Vol. 83, Iss. 16, pp. 1501-1521
Closed Access | Times Cited: 35
Gout therapeutics and drug delivery
Xiuju Peng, Xiaotong Li, Bing Xie, et al.
Journal of Controlled Release (2023) Vol. 362, pp. 728-754
Closed Access | Times Cited: 28
The therapeutic potential of immunoengineering for systemic autoimmunity
David A. McBride, Ryan M. Jones, Nunzio Bottini, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 4, pp. 203-215
Closed Access | Times Cited: 9
Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis
Kelly R. Rhodes, Stephany Y. Tzeng, Marcos Iglesias, et al.
Science Advances (2023) Vol. 9, Iss. 22
Open Access | Times Cited: 20
Hemophilia A gene therapy: current and next-generation approaches
Steven W. Pipe, Gil Gonen-Yaacovi, Oscar G. Segurado
Expert Opinion on Biological Therapy (2021) Vol. 22, Iss. 9, pp. 1099-1115
Open Access | Times Cited: 41
Therapeutic enzymes: Discoveries, production and applications
Siddhi Tandon, Anjali Sharma, Shikha Singh, et al.
Journal of Drug Delivery Science and Technology (2021) Vol. 63, pp. 102455-102455
Closed Access | Times Cited: 37
IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice
John S. Butterfield, Kentaro Yamada, Thaís B. Bertolini, et al.
Molecular Therapy (2022) Vol. 30, Iss. 12, pp. 3552-3569
Open Access | Times Cited: 28
A glance into the future of gout
Francisca Sivera, Mariano Andrés, Nicola Dalbeth
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 27
Charcot–Marie–Tooth neuropathies: Current gene therapy advances and the route toward translation
Marina Stavrou, Alexia Kagiava, Irene Sargiannidou, et al.
Journal of the Peripheral Nervous System (2023) Vol. 28, Iss. 2, pp. 150-168
Open Access | Times Cited: 16
Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)
Alan Kivitz, Wesley DeHaan, Rehan Azeem, et al.
Rheumatology and Therapy (2023) Vol. 10, Iss. 4, pp. 825-847
Open Access | Times Cited: 16
Emerging strategies for treating gout
Edward M. Huddleston, Angelo Gaffo
Current Opinion in Pharmacology (2022) Vol. 65, pp. 102241-102241
Closed Access | Times Cited: 22
Rescue of infant progressive familial intrahepatic cholestasis type 3 mice by repeated dosing of AAV gene therapy
Nicholas D. Weber, Leticia Odriozola, Irene Ros‐Gañán, et al.
JHEP Reports (2023) Vol. 5, Iss. 5, pp. 100713-100713
Open Access | Times Cited: 11
Bringing enzymes to the proximity party
Gabrielle S. Tender, Carolyn R. Bertozzi
RSC Chemical Biology (2023) Vol. 4, Iss. 12, pp. 986-1002
Open Access | Times Cited: 11
Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases
David A. Horwitz, Sean Bickerton, Antonio La Cava
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 26
Anti-Drug Antibody Response to Therapeutic Antibodies and Potential Mitigation Strategies
Erin L. Howard, Melanie M. Goens, Leonardo Susta, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 299-299
Open Access
Advancements in Uricase formulations: overcoming therapeutic challenges in enzyme replacement therapy
Woo Ho Cho, HyeSoon Kim, So‐Yeol Yoo, et al.
Journal of Pharmaceutical Investigation (2025)
Open Access
Click Chemistry-Assisted Rejuvenation of Aging T Cells Sensitizes Aged Mice to Tumor Immunotherapy
Xue‐Feng Bai, Jing Ma, Cheng Zhang, et al.
Journal of the American Chemical Society (2025)
Closed Access
Overcoming Immunological Challenges Limiting Capsid-Mediated Gene Therapy With Machine Learning
Anna Z. Wec, Kathy S. Lin, Jamie C. Kwasnieski, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 21
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout
Naomi Schlesinger, Lissa Padnick‐Silver, Brian LaMoreaux
BioDrugs (2022) Vol. 36, Iss. 2, pp. 95-103
Open Access | Times Cited: 15
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout
Herbert S. B. Baraf, Puja Khanna, Alan Kivitz, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 4, pp. 1058-1067
Open Access | Times Cited: 9
Gene therapy for organic acidemias: Lessons learned from methylmalonic and propionic acidemia
Randy J. Chandler, Charles P. Venditti
Journal of Inherited Metabolic Disease (2023) Vol. 47, Iss. 1, pp. 63-79
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top